Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Payables (2022 - 2025)

Historic Payables for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $8.5 million.

  • Orchestra BioMed Holdings' Payables rose 7939.87% to $8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year increase of 7939.87%. This contributed to the annual value of $5.1 million for FY2024, which is 7703.45% up from last year.
  • As of Q3 2025, Orchestra BioMed Holdings' Payables stood at $8.5 million, which was up 7939.87% from $5.3 million recorded in Q2 2025.
  • Orchestra BioMed Holdings' 5-year Payables high stood at $8.5 million for Q3 2025, and its period low was $103607.0 during Q1 2022.
  • Over the past 4 years, Orchestra BioMed Holdings' median Payables value was $3.4 million (recorded in 2024), while the average stood at $3.7 million.
  • Over the last 5 years, Orchestra BioMed Holdings' Payables had its largest YoY gain of 256873.86% in 2023, and its largest YoY loss of 2691.53% in 2023.
  • Over the past 4 years, Orchestra BioMed Holdings' Payables (Quarter) stood at $4.0 million in 2022, then dropped by 26.92% to $2.9 million in 2023, then surged by 77.03% to $5.1 million in 2024, then soared by 65.04% to $8.5 million in 2025.
  • Its Payables was $8.5 million in Q3 2025, compared to $5.3 million in Q2 2025 and $5.6 million in Q1 2025.